NDAORALCAPSULE
Approved
Jan 1946
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRIDIONE (trimethadione) is an oral small-molecule anticonvulsant approved in 1946 for seizure management. It represents a legacy therapeutic class with narrow current indications and limited modern clinical use. The drug's mechanism and exact indication profile are not fully detailed in current data, reflecting its age and evolving clinical role.
LOE Approaching
Product is in LOE phase with minimal linked job opportunities, indicating a contracted team focused on maintenance rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TRIDIONE presents minimal career growth opportunity due to LOE approaching and zero linked job openings. Roles available are typically focused on compliance, market access, and defending existing market position rather than innovation or expansion.
Brand Manager (Specialty/Legacy)Market Access Manager
Worked on TRIDIONE at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.